论文部分内容阅读
临床实践表明磺脲类药物是治疗非胰岛素依赖糖尿病(NIDDM)即Ⅱ型糖尿病有效的口服降糖剂。近10余年来国外第二代磺脲类新药相继问世,并广泛应用于临床。天津华津药厂用法国施维雅药厂原料所研制的国产达美康(商品名Diamicron),化学名甲磺吡脲系第二代磺脲类口服降糖新药,其降糖作用迅速,对胰岛B细胞有促泌作用,可改善糖代谢,同时还可延缓血管并发病,目前已成为临床治疗NIDDM的常用有效药物。我们在1990年联合对华津药厂的达美康进行临床治疗糖尿病验证,并用优降糖作对照观察评价,现将结果报告如下。
Clinical practice shows that sulfonylureas are effective oral glucose-lowering agents for the treatment of non-insulin-dependent diabetes mellitus (NIDDM), type II diabetes. Nearly 10 years of foreign second generation sulfonylurea drugs have come out and are widely used in clinical. Tianjin Huacheng Pharmaceutical Factory developed by the French Siweiya pharmaceutical raw materials developed by the United States (the name Diamicron), the chemical name of the second-generation sulfapyronin sulfamethoxazole oral hypoglycemic agents, the hypoglycemic effect of rapid, On the islet B cells have secretory effect, can improve glucose metabolism, but also can delay vascular pathogenesis, has now become a commonly used and effective clinical treatment of NIDDM drugs. We in 1990, the United States Huachen pharmaceutical companies in the clinical treatment of diabetes mellitus validation, and use of glyburide for the control of observation and evaluation, the results are reported as follows.